Blood Coagulation & Fibrinolysis最新文献

{"title":"The factor V H1327R (rs1800595) polymorphism is associated with venous thromboembolic events: a case-control study in southern Iran.","authors":"Ahmadreza Fahandej Sadi, Jamileh Saberzadeh, Ardeshir Bahmanimehr, Mohammad Ali Takhshid, Hadis Soleimanzadeh, Parisa Tandel, Hamed Javanmardi, Nahid Nasiri","doi":"10.1097/MBC.0000000000001336","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001336","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) is a complex condition influenced by genetic and acquired factors. While genetic variations in proteins like S, C, and antithrombin are known to play a role in VTE, some cases remain unexplained. This study aims to investigate other genetic variations, including Protein Z (rs3024731), FV (rs1800595), and FGA (rs6050), to understand their potential association with VTE risk. The study included 118 VTE patients and 118 healthy individuals with no history of thromboembolic disorders. Blood samples were collected from the patients for DNA extraction, and genotyping was carried out using the amplification refractory mutation system-PCR (ARMS-PCR) technique. The results were validated through DNA sequencing. Data analysis was done using SPSS 27 software. Analysis has revealed significant differences in the genotypic and allelic frequencies of the rs1800595 polymorphism between the control and case groups. It was found that individuals with the AG genotype had a 2.22 times higher likelihood of experiencing thrombophilia events [odds ratio (OR) = 2.229, P = 0.039, confidence interval (CI) = 95%], while the G allele increased the risk by 2.103 times (OR = 2.103, P = 0.047, CI = 95%). No significant correlation was observed between VTE and the rs3024731 and rs6050 polymorphisms. The rs1800595 polymorphism in the FV gene may be associated with an increased risk of thrombophilia in VTE patients.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144214800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor in lupus anticoagulant positive patient.","authors":"Ju Hyeong Lee, Ja-Yoon Gu, Junshik Hong, Kwon-Wook Joo, Eun Young Lee, Hyun Kyung Kim","doi":"10.1097/MBC.0000000000001360","DOIUrl":"10.1097/MBC.0000000000001360","url":null,"abstract":"<p><p>Isolated prothrombin antibody or isolated factor XI inhibitor have been reported separately in lupus-anticoagulant positive patients. We report the first case of a lupus-anticoagulant positive patient that both simultaneously occurred. A 30-year-old man with a history of systemic lupus erythematosus was positive for lupus-anticoagulant. He exhibited significantly high bleeding score compared to previous reports of lupus-anticoagulant positive patients with isolated prothrombin or factor XI deficiency. Examination via one-stage clotting assays revealed decreased levels of both prothrombin and factor XI. Factor parallelism was proven for prothrombin but not for factor XI. The factor XI inhibitor was quantified at 2.1 Bethesda units in the Bethesda assay, and antiprothrombin nonneutralizing antibody tested positive in ELISA. This study suggests that the concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor can aggravate bleeding tendency synergistically in lupus-anticoagulant positive patient. Bethesda assay or ELISA may be considered depending on the factor-parallelism in one-stage clotting assay.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"130-133"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing fondaparinux and low molecular weight heparin for thromboprophylaxis after hip and knee arthroplasty: a systematic review and meta-analysis.","authors":"Muhammad Hassan Waseem, Zain Ul Abideen, Nohela Rehman, Sarosh Ali, Esha Dilawar, Haseeb Javed Khan, Burhan Khalid, Muhammad Ansab, Sania Aimen, Areehah Zafar Masood","doi":"10.1097/MBC.0000000000001352","DOIUrl":"10.1097/MBC.0000000000001352","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) remains a significant cause of perioperative morbidity and mortality despite the availability of prophylactic medications. There has been a debate about which thromboprophylaxis medication, Fondaparinux or low-molecular weight heparin (LMWH), is better after hip and knee arthroplasty. We have compared these two treatment regimens in our study. Electronic databases like PubMed, Cochrane, and ScienceDirect were searched from inception to August 2024. The weighted mean difference (WMD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes were pooled using the Review Manager software version 5.4.1, and a random effects model was employed. The Newcastle-Ottawa Scale and Cochrane Risk of Bias Tool (ROB 2.0) were used to assess the quality of the included studies. Publication bias was evaluated visually through funnel plots and statistically through Egger's regression. GRADE assessment was used to analyze the certainty of evidence. A total of 17 studies, 9 Cohorts, and 8 Randomized controlled trials (RCTs) pooling a total of 74 499 patients were included in this meta-analysis. Fondaparinux showed a statistically significant reduction in the risk of VTE [0.59; 95% confidence interval (CI): [0.48, 0.71]; P  < 0.00001; I2  = 36%] and deep venous thrombosis (DVT) (RR = 0.75, 95% CI: [0.56, 1.00]; P  = 0.05; I2  = 68%) compared to LMWH. Major bleeding (RR = 2.06, 95% CI: [1.19, 3.57]; P  = 0.01; I2  = 43%), surgical site bleeding (RR = 1.67, 95% CI: [1.04, 2.66]; P  = 0.03; I2  = 9%), and postoperative transfusions (RR = 1.07, 95% CI: [1.02, 1.12]; P  = 0.004; I2  = 0%) were significantly higher in the Fondaparinux group. Symptomatic VTE, pulmonary embolism, mortality, and operating time showed no significant difference between the two groups. In conclusion, Fondaparinux is superior to LMWH in VTE and DVT prophylaxis. However, it is associated with an increased risk of major bleeding, surgical site bleeding, and postoperative transfusions.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"119-129"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemolysis detection accuracy on Stago sthemO 301.","authors":"Simone Denitto, Gian Luca Salvagno, Emmanuel J Favaloro, Giuseppe Lippi","doi":"10.1097/MBC.0000000000001359","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001359","url":null,"abstract":"","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":"36 4","pages":"134-135"},"PeriodicalIF":1.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum levels of inflammatory markers, sP-selectin, IL-1β, IL-6, and hsCRP are positively correlated with tissue factor transcript level of peripheral blood mononuclear cells in stroke.","authors":"Rasoul Ebrahimi, Tahereh Kalantari, Fatemeh Sarkari, Mahdieh Nematzadeh, Mohammad Jafar Sharifi, Kiana Mohammadian, Parisa Alipour, Fatemeh Safari, Sepide Namdari, Afshin Borhani-Haghighi","doi":"10.1097/MBC.0000000000001370","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001370","url":null,"abstract":"<p><strong>Objectives: </strong>Stroke is an injury occurring due to a sudden interruption of blood supply to the brain. It is the leading cause of disability worldwide and the second most prevalent cause of mortality. The objective of this study is whether momentous inflammatory and coagulation markers may have a correlation with each other in stroke patients.</p><p><strong>Material and methods: </strong>Sixty stroke patients and twenty sex-age matched normal controls were sampled. Interleukin (IL)-6, IL-1β, sP-selectin, and high-sensitivity C-reactive protein (hsCRP), key inflammatory markers, were selected and measured by ELISA, and tissue factor gene expression level was evaluated by real-time PCR in peripheral blood mononuclear cells.</p><p><strong>Results: </strong>The serum levels of sP-selectin, IL-1β, IL-6, and hsCRP increased significantly in patients (P-value < 0.05). In the patient group, a significant correlation was observed between these inflammatory markers and coagulant tissue factor gene expression in peripheral blood mononuclear cells (P-values < 0.05), while it was not significant in the control group.</p><p><strong>Conclusion: </strong>This study proposed that the main inflammatory markers in connection with tissue factor may play a role in the occurrence of thrombosis in stroke patients. Therefore, targeting and inhibiting the key inflammatory factors along with existing anticoagulants may greatly reduce the complications associated with stroke.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between the polymorphism of FXI c.539A>G and venous thromboembolism in the population of central china.","authors":"Na Liu, Yanyan You, Jingdi Liu, Liang Tang, Wei Zeng","doi":"10.1097/MBC.0000000000001368","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001368","url":null,"abstract":"<p><strong>Background: </strong>Venous thromboembolism (VTE) has a genetic component that can differ significantly among populations. The genetic landscape of VTE in China, where incidence is rising, may harbor unique susceptibilities. This study aimed to examine the factor XI (FXI) c.539A>G polymorphism's role in VTE risk and its correlation with FXI levels among central Chinese VTE patients.</p><p><strong>Methods: </strong>We included 1748 VTE patients and 1819 matched controls, and extracted genomic DNA. Direct sequencing identified the FXI c.539A>G mutation in 50 patient samples. FXI antigen levels were quantified using ELISA, and bioinformatics evaluated the mutation's biological significance.</p><p><strong>Results: </strong>The FXI c.539A>G mutation occurred in three heterozygous individuals. It was more prevalent in VTE patients (2.26%) than controls (1.37%), with a significant odds ratio of 1.66 (95% CI: 1.16-2.37, P = 5.03 × 10-3). Patients with the mutation showed increased FXI antigen levels (16.76 ± 5.78 ng/ml) versus the wild-type (10.77 ± 4.98 ng/ml, P = 1.20 × 10-3), without affecting FXI activity (P = 0.57).</p><p><strong>Conclusion: </strong>The FXI c.539A>G variant is associated with VTE in central China, marked by elevated FXI antigen levels but not altered activity. This finding suggests that FXI c.539A>G may serve as a genetic marker for VTE risk. Further studies are needed to explore its role in early screening of VTE and gene-environment interactions.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing prediction of thrombosis associated with breast cancer using prechemotherapy hematologic and coagulation characteristics.","authors":"Regan Bucciol, Hannah Parente, Yousra Tera, E Claire Bunker, Aditi Kini, Brooke E Wilson, Mihaela Mates, Maha Othman","doi":"10.1097/MBC.0000000000001367","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001367","url":null,"abstract":"<p><strong>Introduction: </strong>The applicability of venous thromboembolism (VTE) risk assessment models (RAMs), to breast cancer (BC) populations remains unclear. We aimed to compare the efficacy of current RAMs and examine the potential of additional hematologic parameters and thromboelastography (TEG); a point of care test, in improving VTE prediction in breast cancer (BC) patients.</p><p><strong>Methods: </strong>In this pilot study, female BC patients were recruited before chemotherapy and followed for 6-12 months for VTE. VTE risk was assessed using Khorana score, Vienna CATS, PROTECHT, COMPASS-CAT, New Vienna CATSCORE, MDACC CAT, and hypercoagulability status. TEG and hematologic parameters were analyzed, and a modified RAM was developed.</p><p><strong>Results: </strong>Among 47 patients, 5 (10.6%) developed VTE. PROTECHT was the strongest predictor [area under the curve (AUC) = 0.844], followed by Vienna CATS (AUC = 0.781). Adding immature granulocytes and red blood cell count to PROTECHT optimized prediction (AUC = 0.856).</p><p><strong>Conclusion: </strong>Incorporating hematologic parameters into PROTECHT may improve VTE risk prediction in BC patients, warranting further evaluation in larger studies.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet secretion defects and increased CD63 expression in Hermansky-Pudlak syndrome\" a case report.","authors":"Massoumeh Shahbazi, Minoo Ahmadinejad","doi":"10.1097/MBC.0000000000001366","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001366","url":null,"abstract":"<p><p>Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder characterized by clinical features including oculocutaneous albinism (OCA) and bleeding diathesis due to platelet storage pool deficiency. In this article, we report a 12-year-old boy with recurrent epistaxis who was referred to the Iranian Blood Transfusion Organization (IBTO) reference coagulation laboratory for platelet function analysis. Based on the laboratory diagnostic tests in this study and the patient's clinical presentation, the probability of HPS type 2 is more likely.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemostatic effects of combined Thymus vulgaris and Medicago sativa extracts: in silico and in vivo study.","authors":"Zahra Sadat Mashkani, Jafar Vatandoost, Toktam Hajjar, Mitra Kheirabadi","doi":"10.1097/MBC.0000000000001356","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001356","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the hemostatic effects of combined extracts from Thymus vulgaris and Medicago sativa in an animal model, focusing on their impact on coagulation indices. We hypothesize that the combined extracts will modulate the extrinsic and intrinsic coagulation pathways, improving hemostasis.</p><p><strong>Methods: </strong>Thirty-two male NMRI mice were randomly assigned to four groups (n = 8): negative control (distilled water), 300 mg/kg/day M. sativa (MS300), 100 mg/kg/day T. vulgaris extract (TV100), and combined extracts (TV100 + MS300). After 14 days of treatment, blood samples were collected to measure prothrombin time (PT) and activated partial thromboplastin time (aPTT). Chemical analysis identified active compounds, and molecular docking studies were performed to assess their interaction with coagulation factor VIIa (FVIIa).</p><p><strong>Results: </strong>The treated groups showed significant changes in coagulation indices compared to the control. PT was significantly decreased (P < 0.05), and aPTT was significantly increased (P < 0.05) in the M. sativa, T. vulgaris, and combined extract groups. The combined extract showed the most significant effect. Computational analyses revealed that compounds like Scandenon and Vitamin E interacted with FVIIa, suggesting their role in modulating the extrinsic coagulation pathway. These compounds showed strong binding affinity to FVIIa.</p><p><strong>Conclusion: </strong>Combined extracts of T. vulgaris and M. sativa significantly influence coagulation, especially the extrinsic pathway. The presence of aromatic, hydroxyl, alcoholic, and phenolic groups in these compounds likely contributes to their interaction with coagulation factors. These findings support the potential development of plant-based hemostatic agents for clinical use.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel pathogenic variant in the fibrinogen gamma chain gene p.Glu275Lys causes congenital hypofibrinogenemia.","authors":"Miroslava Drotarova, Rosanna Asselta, Sonia Caccia, Ingrid Skornova, Jana Zolkova, Zuzana Kolkova, Dusan Loderer, Vladimir Podusel, Jan Stasko, Tomas Simurda","doi":"10.1097/MBC.0000000000001362","DOIUrl":"https://doi.org/10.1097/MBC.0000000000001362","url":null,"abstract":"<p><p>Congenital hypofibrinogenemia presents not only with bleeding, but also paradoxically with thrombosis. This heterogeneity of clinical phenotype complicates both diagnosis and management. The thrombotic phenotype is thought to arise from alterations in fibrin structure and stability, leading to abnormal clot formation and an increased risk of thrombosis. Coagulation assays, gene analysis, and protein modeling were utilized to elucidate the pathogenic variant. We highlight the pathophysiology of the novel missense variant in the FGG gene (c.823G/A, p.Glu275Lys), which causes mild hypofibrinogenemia and clinically manifests as an ischemic stroke. Protein modeling displays that the amino-acid substitution of glutamine with lysine at position 275 in mentioned missense variant causes local changes in the fibrinogen structure. The structural changes are mainly minor surface alterations and changes in physicochemical properties, which could potentially affect the recruitment of other proteins or lead to abnormal fibrin polymerization. This study provides novel insights into the pathophysiological mechanism, emphasizing the importance of molecular and structural analyses in understanding and managing atypical presentations of fibrinogen disorders.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}